Literature DB >> 22595968

Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity.

Fernando Morales1, Jillian M Couto, Catherine F Higham, Grant Hogg, Patricia Cuenca, Claudia Braida, Richard H Wilson, Berit Adam, Gerardo del Valle, Roberto Brian, Mauricio Sittenfeld, Tetsuo Ashizawa, Alison Wilcox, Douglas E Wilcox, Darren G Monckton.   

Abstract

Deciphering the contribution of genetic instability in somatic cells is critical to our understanding of many human disorders. Myotonic dystrophy type 1 (DM1) is one such disorder that is caused by the expansion of a CTG repeat that shows extremely high levels of somatic instability. This somatic instability has compromised attempts to measure intergenerational repeat dynamics and infer genotype-phenotype relationships. Using single-molecule PCR, we have characterized more than 17 000 de novo somatic mutations from a large cohort of DM1 patients. These data reveal that the estimated progenitor allele length is the major modifier of age of onset. We find no evidence for a threshold above which repeat length does not contribute toward age at onset, suggesting pathogenesis is not constrained to a simple molecular switch such as nuclear retention of the DMPK transcript or haploinsufficiency for DMPK and/or SIX5. Importantly, we also show that age at onset is further modified by the level of somatic instability; patients in whom the repeat expands more rapidly, develop the symptoms earlier. These data establish a primary role for somatic instability in DM1 severity, further highlighting it as a therapeutic target. In addition, we show that the level of instability is highly heritable, implying a role for individual-specific trans-acting genetic modifiers. Identifying these trans-acting genetic modifiers will facilitate the formulation of novel therapies that curtail the accumulation of somatic expansions and may provide clues to the role these factors play in the development of cancer, aging and inherited disease in the general population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595968     DOI: 10.1093/hmg/dds185

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  75 in total

1.  Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Authors:  Gayle Overend; Cécilia Légaré; Jean Mathieu; Luigi Bouchard; Cynthia Gagnon; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

Review 2.  Repeat instability during DNA repair: Insights from model systems.

Authors:  Karen Usdin; Nealia C M House; Catherine H Freudenreich
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-01-22       Impact factor: 8.250

Review 3.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

4.  Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions.

Authors:  Jovan Pešović; S Perić; M Brkušanin; G Brajušković; V Rakočević-Stojanović; Dušanka Savić-Pavićević
Journal:  Neurogenetics       Date:  2017-09-23       Impact factor: 2.660

5.  A Defective mRNA Cleavage and Polyadenylation Complex Facilitates Expansions of Transcribed (GAA)n Repeats Associated with Friedreich's Ataxia.

Authors:  Ryan J McGinty; Franco Puleo; Anna Y Aksenova; Julia A Hisey; Alexander A Shishkin; Erika L Pearson; Eric T Wang; David E Housman; Claire Moore; Sergei M Mirkin
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

Review 6.  On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability.

Authors:  Alexandra N Khristich; Sergei M Mirkin
Journal:  J Biol Chem       Date:  2020-02-14       Impact factor: 5.157

7.  Modelling and inference reveal nonlinear length-dependent suppression of somatic instability for small disease associated alleles in myotonic dystrophy type 1 and Huntington disease.

Authors:  Catherine F Higham; Darren G Monckton
Journal:  J R Soc Interface       Date:  2013-09-18       Impact factor: 4.118

Review 8.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

9.  Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.

Authors:  Yuanzheng Gao; Xiuming Guo; Katherine Santostefano; Yanlin Wang; Tammy Reid; Desmond Zeng; Naohiro Terada; Tetsuo Ashizawa; Guangbin Xia
Journal:  Mol Ther       Date:  2016-05-12       Impact factor: 11.454

10.  Parental age effects, but no evidence for an intrauterine effect in the transmission of myotonic dystrophy type 1.

Authors:  Fernando Morales; Melissa Vásquez; Patricia Cuenca; Domingo Campos; Carolina Santamaría; Gerardo Del Valle; Roberto Brian; Mauricio Sittenfeld; Darren G Monckton
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.